Nasdaq

RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research ...

Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety of ...
Nasdaq

KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide ...
FiercePharma

Phibro Animal Health Corporation Announces Entry Into Collaboration Agreement, License Agreement and Intellectual Property Acquisition Agreement

TEANECK, N.J., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation ("Phibro") (Nasdaq:PAHC) today announced it has acquired exclusive North American distribution rights for vaccines ...